Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
KRAS
Pharma
FDA greenlights RevMed’s pancreatic cancer gamechanger
Following dynamite data that earned a standing ovation at ASCO, RevMed's star Ras inhibitor daraxonrasib has been approved by the FDA.
Darren Incorvaia
Aug 26, 2026 11:30am
BMS details Krazati confirmatory fail in colorectal cancer
Jul 7, 2026 10:46am
Fierce Biotech
ASCO: RevMed confident in RAS leadership as rivals square up
May 31, 2026 8:00am
China biotech deals, Shionogi's ALS buy—Fierce Pharma Asia
Jan 9, 2026 3:00am
Verastem nixes KRAS G12C plans in non-small cell lung cancer
Jan 2, 2026 10:10am
Angus on Angus: A Fierce oncology discussion
Apr 25, 2025 9:41am
